A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5mcg (Delivered by the Respimat Inhaler) and Tiotropium 18mcg (Delivered by the HandiHaler) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat Inhaler) and Tiotropium 18mcg (Delivered by the HandiHaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Latest Information Update: 10 Aug 2015
At a glance
- Drugs Olodaterol (Primary) ; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms ANHELTO 1
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 May 2013 Planned number of patients changed from 1120 to 1134 as reported by ClinicalTrials.gov.
- 15 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.